HEALTH News & Notes

FDA Approves JUVÉDERM® XC, The Latest Advancement In Hyaluronic Acid Dermal Fillers From Allergan, Inc., For A More Comfortable Injection Experience

(NAPSA)—There's encouraging news for anyone looking to instantly smooth the wrinkles around the nose and mouth but is concerned about pain. Now available nationwide, JUVÉDERM® XC from Allergan, Inc. contains lidocaine for enhanced comfort during treatment of the "parentheses" lines between the nose and mouth.

"The 'no pain, no gain' mentality has definitely played a role in the way women over the years have thought about aesthetic treatments. However, that is changing with recent advancements in aesthetic medicine," said Amy Wechsler, M.D., board-certified dermatologist and psychiatrist. "In the clinical trial leading up to the U.S. Food and Drug Administration (FDA) approval of JUVÉDERM® XC, 93 percent of patients reported less pain when treated with JUVÉDERM® XC compared to the non-lidocaine JUVÉDERM® formulation[1]. Patients can now receive the same smooth

results as demonstrated with JUVÉDERM® but enjoy a more comfortable injection experience."

JUVÉDERM® XC with 0.3 percent lidocaine numbs the treatment area within seconds, potentially reducing the need for an additional anesthetic. Before the introduction of JUVÉDERM® XC, it often took up to 30 minutes for an anesthetic block to take effect. The new formulation provides the same smooth, long-lasting results as demonstrated with existing formulations of JUVÉDERM® and now offers a more comfortable treatment experience and potentially less time spent in the physician's office compared to the non-lidocaine JUVÉDERM® formulation.

"JUVÉDERM® is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment[2]," said Dr. Wechsler. "My patients are satisfied with treatment results, and JUVÉDERM® has steadily gained popularity since its introduction."

For more information about JUVÉDERM® dermal fillers and to find a local physician, please visit www.Juvederm.com and become a fan of the official JUVÉDERM® Facebook page.

Important JUVÉDERM® Information

JUVÉDERM® injectable gel (including JUVÉDERM® Ultra, JUVÉDERM® Ultra Plus, JUVÉDERM® Ultra XC, and JUVÉDERM® Ultra Plus XC) is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). Side effects were usually mild to moderate lasting 7 days or less and included temporary injection site reactions like redness, pain, firmness, swelling and bumps. JUVÉDERM® is not for people with severe allergies. For more information, please click on the "About Safety" link at www.juvederm.com or call the Allergan Product Support line at (877) 345-5372. JUVÉDERM® injectable gel is available by prescription only.

1. Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multicenter, doubleblind, randomized controlled study of the safety and effectiveness of JUVÉDERM injectable gel with and without lidocaine. J Cosmet Dermatol. 2009 Sep;8(3):205-10.

2. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for the JUVÉDERM vs Zyplast Nasolabial Fold Study Group. JUVÉDERM Injectable gel: A multicenter, doubleblind, randomized study of safety and effectiveness. Aesthetic Surg J. 2008; 28(1): 17-23.